Clinical trials: Anti-coagulation Therapy
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Arterial Thromboembolic Events, Atrial Fibrillation
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much…
- Trial name
- NCT00786474
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 1,884 people, healthy volunteers welcome
- Sponsor
- Duke University
Sepsis, Acute Kidney Injury
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
This multicenter, randomized, open-label, active-controlled, parallel-group trial will evaluate the efficacy and safety of nafamostat mesylate anticoagulation compared with regional citrate anticoagulation in adult patients with…
- Conditions
- Sepsis, Acute Kidney Injury, Continuous Renal Replacement Therapy (CRRT)
- Trial name
- NICE-AKI (NCT07518303)
- Testing
- Citrate anticoagulation, Nafamostat Mesylate
- Volunteers
- 1,162 people
- Sponsor
- Jianfeng Xie
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care.
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Trial name
- kcentra (NCT03064035)
- Testing
- 4-factor prothrombin complex concentrate (4FPCC)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- HealthPartners Institute
Hemophilia A, Hemophilia B
Data Registry in Chinese Hemophilia A and B Patients
This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.
- Trial name
- NCT07101224
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Portal Vein Thrombosis, Liver Cirrhosis
The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT
The purpose of this study is to determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic patients with portal vein thrombosis and to explore its effect on long-term rebleeding rate and mortality.
- Trial name
- NCT02630095
- Testing
- Nadroparin Calcium and Warfarin, Doppler ultrasound and CT
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Zhongshan Hospital
Atrial Fibrillation on Apixaban Treatment
Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation
"AF is the most common arrhythmia, with an overall prevalence of approximately 2%. It is particularly prevalent in individuals over 60 years old, affecting about 5% of this population.
- Trial name
- NCT06869083
- Testing
- AF application enhancing AF education and drug adhrence, AF application without enhancing AF education and drug adhrence
- Where
- South Korea
- Volunteers
- 5,200 people
- Sponsor
- Yonsei University
Immune Thrombocytopenia (ITP)
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia.
- Trial name
- LCAR1901 (NCT06973356)
- Testing
- Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Severe Hemophilia A, Severe Hemophilia A With Inhibitor
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy.
- Conditions
- Severe Hemophilia A, Severe Hemophilia A With Inhibitor, Severe Hemophilia A Without Inhibitor
- Trial name
- NAVIGATE (NCT05802836)
- Testing
- no interventions
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Christoph Königs
Continuous Renal Replacement Therapy (CRRT), Magnesium
Magnesium Kinetics During Citrate-Anticoagulated CRRT
The goal of this observational study is to assess how continuous renal replacement therapy (CRRT), a type of dialysis used in critically ill patients, affects magnesium levels in adults treated in intensive care units (ICUs).
- Trial name
- NCT07906340
- Testing
- Serial blood and dialysis circuit fluid sampling
- Volunteers
- 35 people
- Sponsor
- Region Skane
Anticoagulation
Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel
Clonidin works as a presynaptic agonist of alpha-sympathomimetic receptors of the brain but also in many other tissues. It is part of balanced anesthesia in general anesthesiology as well as a sedastive agent in intensive care…
- Trial name
- NCT01314235
- Where
- Germany
- Sponsor
- Goethe University
Non-valvular Atrial Fibrillation
Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs (Novel Oral Anticoagulants) in routine clinical practice in England
- Trial name
- NCT03508258
- Testing
- Non-interventional
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Coronary Artery Disease
Antithrombotic Strategy for AF Patients With High Risk CAD
Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism.
- Trial name
- ADAPT AFFIRM (NCT06866665)
- Testing
- Anticoagulation Monotherapy, Combination therapy
- Volunteers
- 1,400 people
- Sponsor
- Yonsei University
Embolism and Thrombosis, Anticoagulation
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation…
- Trial name
- NCT06209892
- Testing
- Extended anticoagulation
- Volunteers
- 220 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Hemophilia A
Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII)…
- Trial name
- HAAC (NCT07314983)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Strasbourg, France
Male Infertility, Heart Valve Disease
Warfarin Effects on Male Fertility After Cardiac Surgery
Young male patients undergoing cardiac surgery may require oral anticoagulation with warfarin either lifelong, such as after mechanical valve replacement, or for a limited postoperative period, for example following valve repair…
- Trial name
- NCT07330869
- Testing
- Semen analysis, sperm DNA fragmentation and hormonal evaluation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Città di Lecce Hospital, GVM Care & Research
Atrial Fibrillation, Strokes Thrombotic
D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy
This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.
- Trial name
- DIRECT (NCT03280641)
- Testing
- Dabigatran Etexilate 110mg, Warfarin Sodium
- Where
- China
- Volunteers
- 1,194 people
- Sponsor
- Wuhan Asia Heart Hospital
Pulmonary Embolism, Intermediate-high Risk
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
Pilot randomized study of the sidlenafil efficacy in combination with oral anticoagulants in the treatment of patients with intermediate-high risk of pulmonary embolism
- Conditions
- Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil
- Trial name
- PSCAT (NCT02946944)
- Testing
- Sildenafil/apixaban, apixaban
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation